Navigation Links
Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference
Date:8/6/2014

RICHMOND, Calif., Aug. 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:40 pm ET on Tuesday, August 12, 2014, at the 2014 Wedbush Life Sciences Management Access Conference.  The conference is being held in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases.  The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Reports First Quarter 2012 Financial Results
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
(Date:11/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted an additional abbreviated new ... Administration (FDA), which brings the Company,s total number of ... now pending at the FDA. ... commented, "Our team here at IGI has continued to ...
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... , , , ... ) announced that it will be hosting a conference call to discuss today,s ... begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , ... accessed through a link that is posted on the home page of Nektar,s ...
... ... firms have to follow a rigorous documentation process to comply with a ... corporate agreements these firms are faced with the daunting task of sharing ... affordable unlimited use facility to share thousands of confidential documents securely and ...
... question, researchers with the U.S. Department of Energy,s ... that the selective placement of strain can alter ... correlated electron materials. This unique class of materials ... display properties such as colossal magnetoresistance and high-temperature ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2Life Science Firms are Turning to Firmex to do Deals Online 2Life Science Firms are Turning to Firmex to do Deals Online 3Strain on nanocrystals could yield colossal results 2Strain on nanocrystals could yield colossal results 3
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/3/2014)... from Australia report that low birth weight and preterm ... hip replacements in adulthood. Findings published in the American ... Research , indicate that low birth weight and pre-term ... due to OA as adults. , According to ... 25 are diagnosed with clinical OA. Symptoms of OA ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... University of California, Davis have discovered that a prototype ... causes of heart failure. Heart failure, which ... the body, affects 5 million people in the United ... The research in the laboratories of cardiologist ...
... but is dangerous to your eyes and skin, says a ... absolutely no benefit over bleaching without UV, and damages skin ... reports a study in Photochemical & Photobiological Sciences . ... be better off ignoring claims of better bleaching with UV ...
... Texas AgriLife Research scientists, talk about their study which reveal antioxidant and phytonutrient properties in stone fruits, ... Click here for more information. ... , , , , ... , , ...
Cached Biology News:UC Davis research shows that newly discovered drug reduces heart enlargement 2Plums poised to give blueberries run for the money 2Plums poised to give blueberries run for the money 3Plums poised to give blueberries run for the money 4
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
... Clear amber to slightly ... Contains 10 vials per set, each ... adjuvant homogenized in the following proportions ... Arlacel A (mannide monooleate emulsifier), and ...
Biology Products: